⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3992933 | 1.00 | — | — | |
| SCHEMBL19538675 | 0.88 | — | — | |
| SCHEMBL13528788 | 0.88 | — | — | |
| SCHEMBL136646 | 0.88 | — | — | |
| SCHEMBL79602 | 0.88 | — | — | |
| SCHEMBL12341578 | 0.88 | — | — | |
| SCHEMBL3988875 | 0.85 | — | — | |
| SCHEMBL1080050 | 0.84 | — | — | |
| SCHEMBL3149044 | 0.84 | — | — | |
| SCHEMBL12341644 | 0.84 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2448930-B1 | N-((S)-2-Oxo-tetrahydro-furan-3-yl)-amide derivatives as inhibitors of the bacterial quorum sensing for treating plant or animal diseases and for preventing the formation of biofilms on medical devices | THE NAT INST FOR BIOTECHNOLOGY IN THE NEGEV LTD (IL) | 2017-02-15 | — | — | EP | disclosed |
| WO-2015042363-A1 | MOLECULES AND COMPOSITIONS THAT INHIBIT GRAM NEGATIVE BACTERIA AND THEIR USES | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2015-03-26 | — | — | WO | disclosed |
| US-20130045208-A1 | Methods for the Treatment of an Infectious Bacterial Disease with an Anti-Lactone or Lactone Derived Signal Molecules Antibody | Haptogen, Ltd. (GB) | 2013-02-21 | — | — | US | disclosed |
| US-20130011400-A1 | Methods For Inducing Autolysis In Infectious Bacteria | HAPTOGEN LTD. (GB) | 2013-01-10 | — | — | US | disclosed |
| US-8168397-B2 | Methods for the treatment of an infectious bacterial disease with an anti-lactone or lactone derived signal molecules antibody | HAPTOGEN LTD. (GB) | 2012-05-01 | — | — | US | disclosed |
| EP-1528935-B1 | METHODS FOR THE TREATMENT OF AN INFECTIOUS BACTERIAL DISEASE WITH AN ANTI-LACTONE OR LACTONE DERIVED SIGNAL MOLECULES ANTIBODY | HAPTOGEN LTD (GB) | 2012-03-21 | — | — | EP | disclosed |
| EP-2281839-A2 | Methods for reducing biofilm formation in infectious bacteria | Haptogen Ltd (GB) | 2011-02-09 | — | — | EP | disclosed |
| US-20110027280-A1 | Methods For Inducing Autolysis In Infectious Bacteria | HAPTOGEN LTD. (GB) | 2011-02-03 | — | — | US | disclosed |
| EP-2261260-A2 | Methods for inducing autolysis in infectious bacteria | Haptogen Ltd (GB) | 2010-12-15 | — | — | EP | disclosed |
| EP-2260868-A2 | Methods for the treatment of an infectious bacterial disease with anti-lactone or lactone derived signal molecules antibody | Haptogen Ltd (GB) | 2010-12-15 | — | — | EP | disclosed |
| US-20100303831-A1 | Methods For The Treatment Of An Infectious Bacterial Disease With An Anti-Lactone Or Lactone Derived Signal Molecules Antibody | HAPTOGEN LTD. (GB) | 2010-12-02 | — | — | US | disclosed |
| US-7812134-B2 | Methods for the treatment of an infectious bacterial disease with an anti-lactone or lactone derived signal molecules antibody | HAPTOGEN LTD. (GB) | 2010-10-12 | — | — | US | disclosed |
| US-20100016424-A1 | PRODUCTION AND USE OF DERIVATIZED HOMOSERINE LACTONES | ENSISHEIM PARTNERS LLC (US) | 2010-01-21 | — | — | US | disclosed |
| US-20090117109-A1 | Methods For Reducing Biofilm Formation In Infectious Bacteria | HAPTOGEN LTD. (GB) | 2009-05-07 | — | — | US | disclosed |
| US-20070218058-A1 | Methods For Inducing Autolysis In Infectious Bacteria | HAPTOGEN LTD. POLWARTH BUILDING (GB) | 2007-09-20 | — | — | US | disclosed |